Cargando…
Advances in treating psoriasis
Psoriasis is a T helper (Th)17/Th1-mediated autoimmune disease affecting the skin and joints. So far, distinct traditional oral compounds and modern biologics have been approved in most countries for the treatment of patients with moderate to severe psoriasis or psoriatic arthritis. Yet, the anti-ps...
Autores principales: | Belge, Katharina, Brück, Jürgen, Ghoreschi, Kamran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883421/ https://www.ncbi.nlm.nih.gov/pubmed/24592316 http://dx.doi.org/10.12703/P6-4 |
Ejemplares similares
-
Recent advances in understanding psoriasis
por: Eberle, Franziska C., et al.
Publicado: (2016) -
Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015) -
Management of Infections in Psoriatic Patients Treated with Systemic Therapies: A Lesson from the Immunopathogenesis of Psoriasis
por: Balato, Anna, et al.
Publicado: (2023) -
The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy
por: Kokolakis, Georgios, et al.
Publicado: (2022) -
IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications
por: von Stebut, Esther, et al.
Publicado: (2020)